Prostaglandin E2 modulation and uses thereof

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 8546077
APP PUB NO 20100304416A1
SERIAL NO

12816820

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Methods, uses, kits and products are described for the prognosis, diagnosis, prevention and treatment of myotronic dystrophy type 1 (DM1), and more particularly for the prognosis, diagnosis, prevention and treatment of the congenital form of myotronic dystrophy type 1 (cDM1), based on changes in/modulation of prostaglandin E2 (PGE2).

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
UNIVERSITE LAVAL2325 RUE DE L’UNIVERSITÉ QUEBEC G1V 0A6

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Beaulieu, Daniel Quebec, CA 6 99
Chapdelaine, Pierre Saint-Romuald, CA 10 46
Puymirat, Jack Quebec, CA 2 0

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 Apr 1, 2025
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00